GFM
LYEL icon

GF Fund Management’s Lyell Immunopharma LYEL Stock Holding History

GF Fund Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.43K Buy
470
+54
+13% +$1.26K ﹤0.01% 561
2025
Q4 		$12.8K Buy
416
+3
+0.7% +$67 ﹤0.01% 556
2025
Q3 		$6.71K Buy
+413
New +$4.72K ﹤0.01% 589

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GF Fund Management's LYEL Position: Q1 2026 in Review

GF Fund Management increased its Lyell Immunopharma (LYEL) stake by 13% in Q1 2026, buying an estimated $1.26K and bringing the position to 470 shares worth $9.43K. The position accounts for ﹤0.01% of the portfolio, ranked #561.

GF Fund Management first reported a position in LYEL in Q3 2025 and has held it in 3 quarters since. The position peaked at $12.8K in Q4 2025. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • GF Fund Management held 470 shares of Lyell Immunopharma worth $9.43K as of Q1 2026.
  • GF Fund Management bought 54 Lyell Immunopharma shares in Q1 2026, an estimated $1.26K.
  • Lyell Immunopharma made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #561 holding.
  • GF Fund Management first reported a position in Lyell Immunopharma in Q3 2025 and has held it in 3 quarters since.
  • GF Fund Management's Lyell Immunopharma position peaked at $12.8K in Q4 2025.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.